AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug

AbbVie (ABBV) dosed the first patient with ABBV-383, an investigational BCMA-CD3-targeted bispecific antibody, in the phase III CERVINO study to treat relapsed/refractory (r/r) multiple myeloma (MM).The CERVINO study will enroll nearly 380 patients with r/r MM who have received at least two lines of prior therapy. Patients will be randomized into two equal groups — either to receive a 60mg dose of intravenously-administered ABBV-383 once every four weeks or the investigator's choice of standard available th ...